Imperial has launched a new licensing opportunities website to share its updated technology portfolio with organisations across the world.
Imperial has today launched a new licensing opportunities website to share its updated technology portfolio with organisations that could benefit from new inventions and technologies developed at one of the world's most innovative universities.
Technologies developed in Imperial labs have been commercialised in fields such as automotive, electronics, diagnostics, therapeutics, medtech and software. Innovations available from the updated portfolio, Imperial.tech, include:
- A novel methodology for stabilising proteins so that vaccines don’t need to be chilled, reducing the need for cold-chain storage and, as a result, the costs of vaccine programmes;
- A target for therapeutic treatment of neuropathic pain, which accounts for up to 25% of patients with chronic pain, by neutralising antibodies;
- High-strength, clogging-resistant concrete, which can be made into permeable paving that mitigates flooding risks; twice as strong and ten times more permeable than existing solutions;
- Seismic metamaterials that can be added around buildings after they have already been built, in order to protect them from ground vibrations and tremors.
An updated technology website for the College is one of the developments made possible by Imperial’s decision last year to take the lead on its own technology transfer work and boost its enterprising activity to the next level.
“This new website represents an important milestone in how the College makes the technologies developed by its world-leading scientists more widely available for improving the quality of all our lives,” said Professor Nick Jennings CB FREng, Vice-Provost for Research and Enterprise at Imperial College London. “Our commitment to tackling global challenges has never been stronger, and the work of Imperial researchers, and therefore many of the technologies in this updated portfolio, has the potential to make a significant contribution to making our lives better in many different ways.”
The College conducts licensing deals with businesses ranging from startups and SMEs to major global companies. Staff from the Industry Partnerships and Commercialisation (IPC) team within Imperial’s Enterprise Division have significant experience in managing the process of translating technology from the laboratory into commercial practice, and are continuing to work remotely to support companies interested in taking a license on technology developed at Imperial.
“Imperial.tech is a great way for us to share the wide range of commercially promising technologies developed by Imperial researchers with industry and potential partners,” said Dr Rebeca Santamaria-Fernandez, Director of Industry Partnerships and Commercialisation, Faculty of Engineering at Imperial College London. “Imperial scientists are deeply interested in the application of research to industry, health and society and the IPC team works closely with groups across the College to support those aims.”
Licensing is just one of many ways that businesses can connect with Imperial’s entrepreneurial ecosystem. Other Imperial Enterprise activities include partnering on collaborative research to generate new knowledge and intellectual property, joining Imperial Business Partners for accelerated access to the best of Imperial’s people and expertise, or working with Imperial Consultants to find an academic expert for solving a business problem.
Article text (excluding photos or graphics) © Imperial College London.
Photos and graphics subject to third party copyright used with permission or © Imperial College London.